While several panels displayed satisfactory performance for overall CRC detection, few excelled in both CRC and APL detection, notably those combining mSDC2 with mSFRP1/2 (CRC: 91.5%/97.3%, APL: 89.2%) or mTFPI2 (CRC: 94.9%/98.1%, APL: 100%), and a 5-biomarker panel (APC, Bat-26, KRAS, L-DNA, p53; CRC: 91.0%/93.0%, APL: 82.0%). This evidence concerns the gene KRAS and colorectal carcinoma.